Postoperative Fracture Risk in Giant Cell Tumor: A Case Report and Review of Literature

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 31

PMID 37905245

Authors

Amit Kumar

Kumar Keshav

Siddhartha Singh

Amarendra Singh

Affiliations

Soon will be listed here.

Abstract

Giant cell tumor (GCT) of the proximal femur poses various challenges in its management and recurrence. We present a rare case of GCT of proximal femur in which recurrence and coxa vara deformity were encountered after index surgery. Management of the recurrence was done with intramedullary fixation with extended curettage and bone grafting. Different aspects of management such as the role of defect size, adjuvants, bone cement/bone graft, implants, and bisphosphonates have been highlighted in this article.

References

Zhang W, Zhang Y, Li P, Rhodesm S, Wang Y, Xue X . Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. Spine (Phila Pa 1976). 2011; 36(17):E1166-72. DOI: 10.1097/BRS.0b013e3182127f91. View

Amanatullah D, Williams J, Fyhrie D, Tamurian R . Torsional properties of distal femoral cortical defects. Orthopedics. 2014; 37(3):158-62. DOI: 10.3928/01477447-20140225-51. View

Wallace M, Henshaw R . Results of cement versus bone graft reconstruction after intralesional curettage of bone tumors in the skeletally immature patient. J Pediatr Orthop. 2013; 34(1):92-100. DOI: 10.1097/BPO.0b013e31829b2f61. View

Toy P, Arthur S, Brown D, Heck R . Reconstruction of noncontained proximal tibial defects with divergent screws and cement. Clin Orthop Relat Res. 2007; 459:167-73. DOI: 10.1097/BLO.0b013e31806165b8. View

Ruskin J, Caravaggi P, Beebe K, Corgan S, Chen L, Yoon R . Steinmann pin augmentation versus locking plate constructs. J Orthop Traumatol. 2016; 17(3):249-54. PMC: 4999372. DOI: 10.1007/s10195-016-0394-y. View

Ahmadi S, Shah S, Wunder J, Schemitsch E, Ferguson P, Zdero R . The biomechanics of three different fracture fixation implants for distal femur repair in the presence of a tumor-like defect. Proc Inst Mech Eng H. 2013; 227(1):78-86. DOI: 10.1177/0954411912454368. View

Xu S, Adams B, Yu X, Xu M . Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol. 2013; 20(5):e442-7. PMC: 3805412. DOI: 10.3747/co.20.1497. View

Mittag F, Leichtle C, Kieckbusch I, Wolburg H, Rudert M, Kluba T . Cytotoxic effect and tissue penetration of phenol for adjuvant treatment of giant cell tumours. Oncol Lett. 2013; 5(5):1595-1598. PMC: 3678778. DOI: 10.3892/ol.2013.1244. View

Murray P, Damron T, Green J, Morgan H, Werner F . Contained femoral defects: biomechanical analysis of pin augmentation in cement. Clin Orthop Relat Res. 2004; (420):251-6. View

10.

Kanwat H, Banjara R, Kumar V, Majeed A, Gamnagatti S, Khan S . Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone. J Orthop Surg (Hong Kong). 2021; 29(2):23094990211007565. DOI: 10.1177/23094990211007565. View

11.

Marcove R, Weis L, Vaghaiwalla M, Pearson R . Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. Clin Orthop Relat Res. 1978; (134):275-89. View

12.

Toy P, France J, Randall R, Neel M, Shorr R, Heck R . Reconstruction of noncontained distal femoral defects with polymethylmethacrylate and crossed-screw augmentation: a biomechanical study. J Bone Joint Surg Am. 2006; 88(1):171-8. DOI: 10.2106/JBJS.D.02313. View

13.

Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y . Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. J Bone Joint Surg Am. 2018; 100(6):496-504. DOI: 10.2106/JBJS.17.00057. View

14.

Wijsbek A, Vazquez-Garcia B, Grimer R, Carter S, Abudu A, Tillman R . Giant cell tumour of the proximal femur: Is joint-sparing management ever successful?. Bone Joint J. 2014; 96-B(1):127-31. DOI: 10.1302/0301-620X.96B1.31763. View

15.

Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S . Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg. 2007; 127(10):867-72. DOI: 10.1007/s00402-007-0419-3. View

16.

Van der Heijden L, Dijkstra P, Campanacci D, Gibbons C, van de Sande M . Giant cell tumor with pathologic fracture: should we curette or resect?. Clin Orthop Relat Res. 2012; 471(3):820-9. PMC: 3563806. DOI: 10.1007/s11999-012-2546-6. View

17.

Benevenia J, Rivero S, Moore J, Ippolito J, Siegerman D, Beebe K . Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications. Clin Orthop Relat Res. 2016; 475(3):776-783. PMC: 5289159. DOI: 10.1007/s11999-016-4755-x. View

18.

Ghouchani A, Rouhi G, Ebrahimzadeh M . Post-operative fracture risk assessment following tumor curettage in the distal femur: a hybrid in vitro and in silico biomechanical approach. Sci Rep. 2020; 10(1):21319. PMC: 7721712. DOI: 10.1038/s41598-020-78188-3. View

19.

Bombardier B, Haase D, Sweeney K, Friedman E, Poppe T, Hughes N . A comparison of depth of necrosis among adjuvant therapies used for the treatment of benign bone tumors. J Surg Oncol. 2021; 123(5):1299-1303. DOI: 10.1002/jso.26397. View

20.

Uglialoro A, Maceroli M, Beebe K, Benevenia J, Patterson F . Distal femur defects reconstructed with polymethylmethacrylate and internal fixation devices: a biomechanical study. Orthopedics. 2009; 32(8). DOI: 10.3928/01477447-20090624-29. View